Post-earnings recap
Reported
Mon, Nov 10, 2025
EPS actual
$-0.52
EPS est.
$-0.66
EPS surprise
+20.85%
1-day move
+17.04%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Mineralys Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, increasing by 17.04%. The company did not provide revenue figures or future guidance, but management's comments suggest a focus on pipeline development. Investors may view the EPS beat as a sign of potential future improvements.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.52 | N/A | +20.85% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS performance, highlighting ongoing efforts in their product development. They remain focused on future growth opportunities.
We are pleased with our progress in the quarter despite the challenges.
Our focus remains on advancing our pipeline.